Gotham Asset Management LLC purchased a new position in Cytokinetics, Incorporated (NASDAQ:CYTK) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 49,907 shares of the biopharmaceutical company’s stock, valued at approximately $641,000. Gotham Asset Management LLC owned about 0.11% of Cytokinetics, at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. FMR LLC raised its position in shares of Cytokinetics, by 2.7% in the fourth quarter. FMR LLC now owns 5,199,414 shares of the biopharmaceutical company’s stock worth $63,173,000 after buying an additional 136,758 shares during the last quarter. A.R.T. Advisors LLC bought a new position in Cytokinetics, during the fourth quarter valued at approximately $394,000. Norges Bank bought a new position in Cytokinetics, during the fourth quarter valued at approximately $976,000. Teachers Advisors LLC raised its position in Cytokinetics, by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 53,278 shares of the biopharmaceutical company’s stock valued at $647,000 after buying an additional 2,025 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in Cytokinetics, during the first quarter valued at approximately $4,302,000. Institutional investors and hedge funds own 59.65% of the company’s stock.

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) traded down 10.00% during midday trading on Thursday, hitting $13.50. 911,721 shares of the stock were exchanged. Cytokinetics, Incorporated has a 12 month low of $8.51 and a 12 month high of $17.20. The company has a market cap of $657.14 million, a PE ratio of 135.00 and a beta of 1.99. The stock has a 50 day moving average price of $13.67 and a 200-day moving average price of $12.95.

Cytokinetics, (NASDAQ:CYTK) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.03. Cytokinetics, had a net margin of 1.53% and a return on equity of 1.94%. The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $5.28 million. On average, analysts predict that Cytokinetics, Incorporated will post ($2.02) EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/03/gotham-asset-management-llc-acquires-shares-of-49907-cytokinetics-incorporated-nasdaqcytk-updated-updated-updated.html.

Several research analysts recently commented on CYTK shares. Zacks Investment Research lowered Cytokinetics, from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 4th. HC Wainwright set a $26.00 price target on Cytokinetics, and gave the stock a “buy” rating in a research report on Thursday. ValuEngine raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics, in a research note on Friday, May 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $21.20.

In other Cytokinetics, news, CEO Robert I. Blum sold 5,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $12.14, for a total value of $60,700.00. Following the completion of the sale, the chief executive officer now directly owns 88,385 shares of the company’s stock, valued at approximately $1,072,993.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 15,000 shares of company stock valued at $197,750 over the last three months. 7.20% of the stock is owned by corporate insiders.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Institutional Ownership by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.